What Does It Take to Scale Cell and Gene Therapies From Discovery to Commercialization

Key Takeaways

• Integrated platforms cut re‑optimization cycles in CGT manufacturing
• Seamless scale from R&D to commercial speeds therapy rollout
• Automated processes lower production costs for gene therapies
• Partnerships with experienced manufacturers reduce time‑to‑market
• Non‑viral cell engineering expands therapeutic options beyond viral vectors

Pulse Analysis

The cell and gene therapy (CGT) sector has moved from experimental labs to late‑stage trials, yet the path to commercial launch remains fraught with high production costs and intricate manufacturing steps. Therapies such as CAR‑T for cancer or AAV‑based treatments for rare diseases often require bespoke processes, driving up price tags that can exceed $500,000 per patient. This cost barrier not only limits payer adoption but also slows the return on the billions invested in R&D, making scalable manufacturing a strategic imperative for the industry.

MaxCyte’s CEO Maher Masoud argues that the solution lies in unified platforms that bridge discovery and large‑scale production. By standardizing cell‑editing workflows and embedding automation early in the development cycle, manufacturers can avoid the costly re‑optimization that typically occurs when a process moves from the bench to a GMP facility. The company’s flow‑electroporation technology, for example, enables consistent transfection across dozens of cell lines, allowing partners to translate a single, validated protocol from pre‑clinical studies straight into clinical manufacturing without reinventing the wheel.

Adopting such end‑to‑end platforms reshapes the business case for CGT. Faster scale‑up shortens time‑to‑market, improves price‑per‑dose economics, and opens the door for non‑viral cell engineering to compete with traditional viral vectors. Investors are increasingly rewarding companies that demonstrate manufacturability at scale, while payers look for therapies that can be delivered at sustainable costs. As more developers align with best‑in‑class manufacturing partners, the industry is poised to expand beyond oncology into broader therapeutic areas, accelerating patient access worldwide.